<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959605</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2019_2</org_study_id>
    <nct_id>NCT03959605</nct_id>
  </id_info>
  <brief_title>Genetic Determinant of Foveolar Hypoplasia in Parents of Albinos Children</brief_title>
  <acronym>ALAFOR</acronym>
  <official_title>Genetic Determinant of Foveolar Hypoplasia in Parents of Albinos Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fovea plana could be the phenoyipic translation of a genetic anomaly in one of the genes
      identified in albinisme
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of genetics variants</measure>
    <time_frame>1 month</time_frame>
    <description>among the genes involved in albinism, identification of those presents in parents of children with albinism</description>
  </primary_outcome>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Albinism, Ocular</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood sample for genetic test</intervention_name>
    <description>detection of pathogenic variants among the 19 genes known to be involved in albinism</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ophtalmological examination</intervention_name>
    <description>measurement of visual acuity, OCT and OCTA</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        parents without symptom of albinism (except fovea plana) of children with albinism
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children with albinism

          -  father and mother of children with albinism

        Exclusion Criteria:

          -  sign of albinism except fovea plana in father or mother of children with albinism

          -  ophthalmological abnormalities making access to the fundus with OCT impossible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine MAUGET FAYSSE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martine MAUGET FAYSSE</last_name>
    <phone>0148036437</phone>
    <phone_ext>+33</phone_ext>
    <email>mmfaysse@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivien VASSEUR</last_name>
    <email>vvasseur@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine MAUGET FAYSSE</last_name>
      <email>mmfaysse@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albinism</mesh_term>
    <mesh_term>Albinism, Ocular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

